TYME Updates at ESMO GI 2019 from Pancreatic Cancer Phase 2 Study

• In this poor prognosis population, SM-88 demonstrated median overall survival (OS) of 6.4 months as of April 25, 2019
• Efficacy indicators showed strong correlation with greater overall survival (OS). These indicators included achieving stable disease (SD) or better and decreases in circulating tumor cells (CTCs)
• Patients who achieved SD or better had a statistically significant (p=0.02) improvement in survival with a 92% reduction in risk of death
• Patients who achieved at least an 80% reduction in CTC burden demonstrated a 60% decrease in risk of death
• The study supports SM-88’s well-tolerated safety profile, with only 4% of patients having a serious adverse event (SAE) that was deemed to be at least possibly related to SM-88
• Based on these results, TYME plans to initiate a randomized pivotal trial for use of SM-88 in patients with pancreatic cancer in Q3’2019

https://www.globenewswire.com/news-release/2019/07/05/1878905/0/en/TYME-Presents-Updated-Data-at-ESMO-GI-2019-from-TYME-88-Panc-Phase-II-Study-Demonstrating-Encouraging-Overall-Survival-Trends-in-Patients-with-Advanced-Pancreatic-Cancer.html